VISTAGEN THERAPEUTICS, INC. Proceeds from Convertible Debt
VISTAGEN THERAPEUTICS, INC. (VTGN) reported Proceeds from Convertible Debt of $100.00 million for the 3-month period ending 2021-06-30, per its 10-Q filed 2021-08-12.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromConvertibleDebt · last filed 2021-08-12
- VISTAGEN THERAPEUTICS, INC. proceeds from convertible debt for the quarter ending 2021-06-30 was $100.00M.
| Period end | Proceeds from Convertible Debt 3 month | Proceeds from Convertible Debt 181 month | Proceeds from Convertible Debt 184 month | Proceeds from Convertible Debt 187 month | Proceeds from Convertible Debt 190 month | Proceeds from Convertible Debt 193 month | Proceeds from Convertible Debt 196 month | Proceeds from Convertible Debt 206 month | Proceeds from Convertible Debt 215 month |
|---|---|---|---|---|---|---|---|---|---|
| 2021-06-30 | $100.00M 10-Q · filed 2021-08-12 | ||||||||
| 2016-03-31 | $34.50M 10-K · filed 2016-06-24 | ||||||||
| 2015-06-30 | $30.00M 10-Q · filed 2015-08-14 | ||||||||
| 2015-03-31 | $29.00M 10-K · filed 2015-06-29 | ||||||||
| 2014-12-31 | $28.00M 10-Q · filed 2015-02-17 | ||||||||
| 2014-09-30 | $27.70M 10-Q · filed 2014-11-19 | ||||||||
| 2014-06-30 | $27.50M 10-Q · filed 2014-08-12 | ||||||||
| 2014-03-31 | $26.00M 10-K · filed 2014-06-25 | ||||||||
| 2013-12-31 | $25.40M 10-Q · filed 2014-02-14 | ||||||||
| 2013-09-30 | $25.20M 10-Q · filed 2013-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |